Latest research on Lamivudine

A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Latest findings

These guidelines recommended a preferred first-line treatment with a combination of Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC) or Emtricitabine (FTC) and Efavirenz (EFV), with second-line treatment using two nucleoside analogues and a boosted protease inhibitor (PI) [1]. [source, 2016]
All the patients included in the study initiated ART with reverse transcriptase inhibitor (RTI) drugs, that is, two nucleoside reverse transcriptase inhibitors (NRTI), Zidovudine (AZT) or Stavudine (d4T) with Lamivudine (3TC) + one non-nucleoside reverse transcriptase inhibitor (NNRTI), either Nevirapine (NVP) or Efavirenz (EFV) as per the standard national AIDS programme guidelines.24 [source, 2016]
Nucleoside/nucleotide analogs (NUCs) provide one of the currently available therapies for the management of CHB, including Lamivudine (LAM), adefovir (ADV), telbivudine, Entecavir (ETV) and Tenofovir (TDF) (4). [source, 2016]
(One participant randomized to the placebo arm had the 80P mutation with possible resistance to Lamivudine and telbivudine). [source, 2016]
Interestingly, there is also some evidence from a recent retrospective study that use of hepatitis B-active antiretroviral therapy for treatment of HIV (Lamivudine, Emtricitabine, and TFV) led to a lower incidence of hepatitis B acquisition than the use of antiretrovirals without hepatitis B activity. [source, 2016]
One isolate from a participant randomized to the placebo arm showed possible resistance to Lamivudine and telbivudine. [source, 2016]
South African ART guidelines at the time of this study recommended an NNRTI plus 2 NRTIs (Stavudine or Zidovudine, each with Lamivudine) as first-line therapy. [source, 2016]
Stored samples were tested for the presence of antiretroviral (ARV) drugs approximately two years after the end of data collection using a qualitative ARV drug assay that tested for Nevirapine, Efavirenz, Lamivudine, and Lopinavir using liquid chromatography-tandem mass spectrometry. [source, 2016]
Among the three patients, two started Lamivudine before the confirmation of breast cancer and one received Entecavir during the postoperative chemotherapy without test for HBV profile regularly. [source, 2016]
Notably, our data did not identify a difference in outcomes among patients in the Tenofovir group who received Lamivudine or Emtricitabine. [source, 2016]